Compass Therapeutics (CMPX) Net Cash Flow (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Net Cash Flow data on file, last reported at $24.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 1107.19% year-over-year to $24.5 million; the trailing twelve-month figure through Mar 2026 stood at $14.1 million (down 18.73% YoY), and the FY2025 full-year result was -$12.8 million, down 166.68% from the prior year.
• Net Cash Flow advanced to $24.5 million in Q1 2026, from -$15.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $24.5 million in Q1 2026 to a low of -$110.1 million in Q2 2022.
• A 5-year average of -$5.3 million and a median of -$4.3 million in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 1206.85% in 2022 and soared 1107.19% in 2026, its largest moves.
• Tracing CMPX's Net Cash Flow over 5 years: stood at $18.5 million in 2022, then plunged by 133.57% to -$6.2 million in 2023, then surged by 198.64% to $6.1 million in 2024, then sank by 354.65% to -$15.6 million in 2025, then surged by 257.52% to $24.5 million in 2026.
• Business Quant data shows CMPX's Net Cash Flow at $24.5 million in Q1 2026, -$15.6 million in Q4 2025, and $23.4 million in Q3 2025.